|
309 Companies |
|
473 Products |
|
473 Products |
|
224 Mechanisms of Action |
|
25 Trials |
|
4900 News |
|
| «12...4567891011121314...9899» |
- ||||||| Torisel (temsirolimus) / Pfizer
Trial completion, Trial primary completion date, Stroma: COMTT: Caphosol in Oral Mucositis Due to Targeted Therapy (clinicaltrials.gov) - Feb 11, 2017
P3, N=64, Completed, Sponsor: Christine B Boers-Doets
Recruiting --> Completed | Trial primary completion date: Feb 2014 --> Aug 2015
- || Technivie (ombitasvir/paritaprevir/ritonavir) / AbbVie, Exviera (dasabuvir) / AbbVie
Trial primary completion date: CORAL-I: A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients (clinicaltrials.gov) - Feb 11, 2017
P2, N=195, Active, not recruiting, Sponsor: AbbVie
Recruiting --> Completed | Trial primary completion date: Feb 2014 --> Aug 2015 Trial primary completion date: Nov 2016 --> Jul 2017
- L-ornithine-L-aspartate / Generic mfg.
Trial completion: HEAL: L-ornithine L-aspartate in Overt Hepatic Encephalopathy (clinicaltrials.gov) - Feb 8, 2017
P4, N=200, Completed, Sponsor: Dayanand Medical College and Hospital
Trial primary completion date: Nov 2016 --> Jul 2017 Active, not recruiting --> Completed
- Trial completion, Enrollment change: A Phase II Study of the Effect of a Low Calorie Diet on Patients Undergoing Liver Resection (clinicaltrials.gov) - Feb 8, 2017
P2, N=65, Completed, Sponsor: Dartmouth-Hitchcock Medical Center
Active, not recruiting --> Completed Recruiting --> Completed | N=114 --> 65
- Hepacid (pegargiminase) / Polaris Pharma
Trial primary completion date: Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Feb 8, 2017
P2, N=40, Active, not recruiting, Sponsor: Polaris Group
Recruiting --> Completed | N=114 --> 65 Trial primary completion date: Nov 2016 --> Jun 2017
- Enrollment change, Trial termination: Intraoperative Dialysis in Liver Transplantation (clinicaltrials.gov) - Feb 7, 2017
P2, N=32, Terminated, Sponsor: University of Alberta
Trial primary completion date: Nov 2016 --> Jun 2017 N=50 --> 32 | Recruiting --> Terminated; Insufficient funding.
- Myalept (metreleptin) / Novelion
Clinical protocol, Trial completion, Trial primary completion date: Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy (clinicaltrials.gov) - Feb 7, 2017
P2, N=23, Completed, Sponsor: University of Michigan
N=50 --> 32 | Recruiting --> Terminated; Insufficient funding. Active, not recruiting --> Completed | Trial primary completion date: Nov 2016 --> Jul 2016
- Aphthasol (amlexanox) / Abeona Therap, Esteve
Clinical protocol, Trial completion: Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients (clinicaltrials.gov) - Feb 7, 2017
P2, N=42, Completed, Sponsor: University of Michigan
Active, not recruiting --> Completed | Trial primary completion date: Nov 2016 --> Jul 2016 Active, not recruiting --> Completed
- Levovir (clevudine) / Bukwang Pharma, Eisai
Phase classification: Durability of Antiviral Activity in Chronic HBV Patients Who Showed Complete Response in L-FMAU-301,302 or 303 Trial (clinicaltrials.gov) - Feb 1, 2017
P=N/A, N=0, Completed, Sponsor: Bukwang Pharmaceutical
Active, not recruiting --> Completed Phase classification: P3 --> P=N/A
- sorafenib / Generic mfg.
Enrollment change, Metastases: A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective (clinicaltrials.gov) - Feb 1, 2017
P1/2, N=5, Completed, Sponsor: Thomas Jefferson University
Phase classification: P3 --> P=N/A N=48 --> 5
- | simtuzumab (GS 6624) / Gilead
Trial termination: Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH (clinicaltrials.gov) - Jan 31, 2017
P2b, N=259, Terminated, Sponsor: Gilead Sciences
N=48 --> 5 Active, not recruiting --> Terminated
- | simtuzumab (GS 6624) / Gilead
Trial termination, Metastases: Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - Jan 31, 2017
P2b, N=222, Terminated, Sponsor: Gilead Sciences
Active, not recruiting --> Terminated Active, not recruiting --> Terminated
- Pegasys (pegylated interferon α -2a) / Roche
Phase classification: A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C (clinicaltrials.gov) - Jan 30, 2017
P=N/A, N=0, No Longer Available, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Terminated Phase classification: P4 --> P=N/A
- |||| Trial completion: Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers (clinicaltrials.gov) - Jan 30, 2017
P2, N=207, Completed, Sponsor: Icahn School of Medicine at Mount Sinai
Phase classification: P4 --> P=N/A Active, not recruiting --> Completed
- ITX-5061 / iTherX
Trial primary completion date: Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection (clinicaltrials.gov) - Jan 30, 2017
P1, N=10, Active, not recruiting, Sponsor: Schiano, Thomas D., MD
Active, not recruiting --> Completed Trial primary completion date: May 2015 --> May 2017
- Trial termination: Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies (clinicaltrials.gov) - Jan 30, 2017
P=N/A, N=13, Terminated, Sponsor: Stanford University
Trial primary completion date: May 2015 --> May 2017 Active, not recruiting --> Terminated; accrual
- ribavirin / Generic mfg.
Enrollment change: CIRES: Study Investigating Immunological Effects of Treatment for Chronic Hepatitis C Patients. (clinicaltrials.gov) - Jan 30, 2017
P=N/A, N=20, Completed, Sponsor: Foundation for Liver Research
Active, not recruiting --> Terminated; accrual N=27 --> 20
- ||| SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Trial completion, Trial primary completion date: SIRFLOX: FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer (clinicaltrials.gov) - Jan 30, 2017
P=N/A, N=532, Completed, Sponsor: Sirtex Medical
N=27 --> 20 Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Jun 2016
- Trial completion, Trial primary completion date: Establishment of Retrospective and Prospective Multicenter Cohort for Chronic Hepatitis B (clinicaltrials.gov) - Jan 26, 2017
P=N/A, N=476, Completed, Sponsor: Yonsei University
Active, not recruiting --> Completed | Trial primary completion date: Jan 2017 --> Jun 2016 Not yet recruiting --> Completed | Trial primary completion date: Mar 2015 --> Jun 2015
- |||| Pegberon (ypeginterferon alpha-2b) / Xiamen Amoytop Biotech
Trial completion: A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B (clinicaltrials.gov) - Jan 26, 2017
P2, N=110, Completed, Sponsor: Xiamen Amoytop Biotech Co., Ltd.
Not yet recruiting --> Completed | Trial primary completion date: Mar 2015 --> Jun 2015 Active, not recruiting --> Completed
- Trial primary completion date: Factors Associated With End Stage Liver Disease (clinicaltrials.gov) - Jan 26, 2017
P=N/A, N=27, Terminated, Sponsor: New York University School of Medicine
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> May 2014
- Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe, Victrelis (boceprevir) / Roche, Merck (MSD)
Trial completion, Trial primary completion date: CUPIC: French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin (clinicaltrials.gov) - Jan 24, 2017
P=N/A, N=675, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Trial primary completion date: Dec 2016 --> May 2014 Active, not recruiting --> Completed | Trial primary completion date: Sep 2013 --> Mar 2014
- pioglitazone / Generic mfg.
Trial termination, Trial primary completion date: PEGLIST C: Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in HCV Patients With Insulin Resistance (clinicaltrials.gov) - Jan 24, 2017
P3, N=40, Terminated, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Active, not recruiting --> Completed | Trial primary completion date: Sep 2013 --> Mar 2014 Active, not recruiting --> Terminated | Trial primary completion date: Jan 2013 --> Jul 2012; Suspension of use of medicine containing Pioglitazone by French regulatory agency
- |||| Sunvepra (asunaprevir) / BMS, Daklinza (daclatasvir) / BMS
Trial completion, Trial primary completion date: Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO) (clinicaltrials.gov) - Jan 24, 2017
P2, N=60, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Active, not recruiting --> Terminated | Trial primary completion date: Jan 2013 --> Jul 2012; Suspension of use of medicine containing Pioglitazone by French regulatory agency Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Feb 2015
- |||| HeberNasvac (ABX203) / Center for Genetic Engineering and Biotechnology, Abivax
Trial completion: Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B (clinicaltrials.gov) - Jan 24, 2017
P2b, N=261, Completed, Sponsor: Abivax S.A.
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Feb 2015 Active, not recruiting --> Completed
- furosemide / Generic mfg.
Trial completion: ANSWER: Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis (clinicaltrials.gov) - Jan 23, 2017
P4, N=431, Completed, Sponsor: University of Bologna
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial termination, Trial primary completion date: Comparison of OraQuick HCV Rapid Antibody Test and Standard Serologic Screening for Hepatitis C: Validity, Acceptability and Impact on Linkage to Care (clinicaltrials.gov) - Jan 23, 2017
P=N/A, N=67, Terminated, Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Active, not recruiting --> Completed Active, not recruiting --> Terminated | Trial primary completion date: Sep 2016 --> Apr 2016; Slow recruitement
- Trial primary completion date: POCKET: Comparison of Three Transfusion Strategies for Central Venous Catheterization in Cirrhotics: A Randomized Clinical Trial (clinicaltrials.gov) - Jan 23, 2017
P=N/A, N=165, Recruiting, Sponsor: Hospital Israelita Albert Einstein
Active, not recruiting --> Terminated | Trial primary completion date: Sep 2016 --> Apr 2016; Slow recruitement Trial primary completion date: Sep 2017 --> Dec 2018
- Trial completion: Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases (clinicaltrials.gov) - Jan 19, 2017
P1, N=16, Completed, Sponsor: Massachusetts General Hospital
Trial primary completion date: Sep 2017 --> Dec 2018 Active, not recruiting --> Completed
- ciprofloxacin oral / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Randomised Open-label Multicenter Study Evaluating Ciprofloxacin in Severe Alcoholic Hepatitis (clinicaltrials.gov) - Jan 19, 2017
P0, N=22, Completed, Sponsor: Helsinki University
Active, not recruiting --> Completed Recruiting --> Completed | N=150 --> 22 | Trial primary completion date: Dec 2017 --> Jan 2017
- | Trial suspension, Trial primary completion date: Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA). (clinicaltrials.gov) - Jan 18, 2017
P1/2, N=100, Suspended, Sponsor: SYZ Cell Therapy Co..
Recruiting --> Completed | N=150 --> 22 | Trial primary completion date: Dec 2017 --> Jan 2017 Active, not recruiting --> Suspended | Trial primary completion date: Dec 2016 --> Jun 2017
- || Sunvepra (asunaprevir) / BMS, Daklinza (daclatasvir) / BMS
Trial primary completion date: Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C (clinicaltrials.gov) - Jan 18, 2017
P=N/A, N=2974, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Suspended | Trial primary completion date: Dec 2016 --> Jun 2017 Trial primary completion date: Nov 2016 --> Feb 2017
- | Livmarli (maralixibat) / Mirum Pharma, Takeda
Trial completion: Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome (clinicaltrials.gov) - Jan 17, 2017
P2, N=36, Completed, Sponsor: Shire
Trial primary completion date: Nov 2016 --> Feb 2017 Active, not recruiting --> Completed
- Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
Enrollment change, Trial termination: Ribatela: Telaprevir Exposure and Severe Anemia in HCV Infected Patients Treated by Tri-therapy (clinicaltrials.gov) - Jan 13, 2017
P=N/A, N=8, Terminated, Sponsor: University Hospital, Grenoble
Active, not recruiting --> Completed N=48 --> 8 | Recruiting --> Terminated
- metformin / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: METFOVIR: Primary Prevention Hepatocellular Carcinoma by Metformin (clinicaltrials.gov) - Jan 11, 2017
P3, N=11, Terminated, Sponsor: Assistance Publique - H
N=48 --> 8 | Recruiting --> Terminated N=444 --> 11 | Recruiting --> Terminated | Trial primary completion date: Jun 2019 --> Apr 2016; Decision of investigator
- | ombitasvir (ABT-267) / AbbVie
Enrollment change, Trial primary completion date, Combination therapy: A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study (clinicaltrials.gov) - Jan 10, 2017
P2, N=35, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
N=444 --> 11 | Recruiting --> Terminated | Trial primary completion date: Jun 2019 --> Apr 2016; Decision of investigator N=93 --> 35 | Trial primary completion date: Oct 2016 --> May 2017
- Intuvax (ilixadencel) / Mendus
Enrollment closed, Trial primary completion date: Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - Jan 10, 2017
P1, N=18, Active, not recruiting, Sponsor: Immunicum AB
N=93 --> 35 | Trial primary completion date: Oct 2016 --> May 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Oct 2017
- Trial completion: Improving Communication About Serious Illness (clinicaltrials.gov) - Jan 10, 2017
P=N/A, N=792, Completed, Sponsor: University of Washington
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Oct 2017 Recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: VDLS: Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes (clinicaltrials.gov) - Jan 10, 2017
P3, N=12, Completed, Sponsor: University of Massachusetts, Worcester
Recruiting --> Completed Recruiting --> Completed | N=10 --> 12 | Trial primary completion date: Jun 2017 --> Oct 2016
- Enrollment closed, Trial primary completion date: Oslo-CoMett: Oslo Randomized Laparoscopic Versus Open Liver Resection for Colorectal Metastases Study (clinicaltrials.gov) - Jan 6, 2017
P=N/A, N=280, Active, not recruiting, Sponsor: Oslo University Hospital
Recruiting --> Completed | N=10 --> 12 | Trial primary completion date: Jun 2017 --> Oct 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Apr 2016
- Mekinist (trametinib) / Novartis, BeiGene
Enrollment change, Surgery, Metastases: SWOG-S1310: Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jan 6, 2017
P2, N=52, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Apr 2016 N=89 --> 52
- tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial primary completion date: A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Jan 5, 2017
P3, N=160, Recruiting, Sponsor: Kyowa Hakko Kirin Co., Ltd
N=89 --> 52 Trial primary completion date: Dec 2016 --> Jul 2017
- Trial primary completion date, Adherence: Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV Coinfection (clinicaltrials.gov) - Jan 4, 2017
P=N/A, N=85, Active, not recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Trial primary completion date: Dec 2016 --> Jul 2017 Trial primary completion date: Dec 2016 --> Mar 2017
- ||| DC Bead (E7040) / Eisai, Boston Scientific
Trial completion, Enrollment change, Trial primary completion date: Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - Dec 30, 2016
P=N/A, N=300, Completed, Sponsor: Eisai Co., Ltd.
Trial primary completion date: Dec 2016 --> Mar 2017 Recruiting --> Completed | N=100 --> 300 | Trial primary completion date: Apr 2016 --> May 2015
- Trial completion, Enrollment change, Biopsy: Acoustic Liver Biopsy in Normals and in Patients With Cirrhosis Using Endoscopic Ultrasound (clinicaltrials.gov) - Dec 29, 2016
P=N/A, N=7, Completed, Sponsor: Northwell Health
Recruiting --> Completed | N=100 --> 300 | Trial primary completion date: Apr 2016 --> May 2015 Suspended --> Completed | N=30 --> 7
- Trial primary completion date: A Health Intervention to Prevent Depression Hepatitis C Patients (clinicaltrials.gov) - Dec 29, 2016
P2/3, N=1, Terminated, Sponsor: University of Texas Southwestern Medical Center
Suspended --> Completed | N=30 --> 7 Trial primary completion date: Jun 2016 --> Oct 2015
- Enrollment change, Trial primary completion date: MARSPAD: Comparison of Two Liver Dialysis Systems : MARS Versus SPAD in Severe Liver Failure (clinicaltrials.gov) - Dec 29, 2016
P=N/A, N=50, Recruiting, Sponsor: Hospices Civils de Lyon
Trial primary completion date: Jun 2016 --> Oct 2015 N=40 --> 50 | Trial primary completion date: Dec 2016 --> Dec 2017
- Pegasys (pegylated interferon α -2a) / Roche
Trial completion, Enrollment change, Trial primary completion date: Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1) (clinicaltrials.gov) - Dec 29, 2016
P4, N=542, Completed, Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
N=40 --> 50 | Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Completed | N=750 --> 542 | Trial primary completion date: Dec 2013 --> Oct 2016
- ribavirin / Generic mfg., daclatasvir/sofosbuvir / Generic mfg.
Trial primary completion date: Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics (clinicaltrials.gov) - Dec 28, 2016
P4, N=39, Active, not recruiting, Sponsor: Tarek I. Hassanein, M.D., FACP, FAG, AGAF
Recruiting --> Completed | N=750 --> 542 | Trial primary completion date: Dec 2013 --> Oct 2016 Trial primary completion date: Jan 2017 --> Jun 2017
- Trial completion, Enrollment change, Biopsy: Comparing Pain in Patients Undergoing Percutaneous Versus Transjugular Techniques of Liver Biopsy (clinicaltrials.gov) - Dec 23, 2016
P=N/A, N=32, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Trial primary completion date: Jan 2017 --> Jun 2017 Enrolling by invitation --> Completed | N=20 --> 32